HistoSonics announced the treatment of the first kidney patient using the company’s histotripsy platform in the United Kingdom. Professor Tze Min Wah, senior consultant radiologist and clinical lead for the interventional oncology program at Leeds Teaching Hospitals NHS Trust, performed the procedure. It marks the initial treatment in HistoSonics’ sponsored “CAIN” trial. The Phase I […]
HistoSonics Inc.
FDA approves HistoSonics IDE trial for sonic beam therapy that treats renal tumors
HistoSonics announced today that it received FDA approval for an investigational device exemption (IDE) trial of its Edison system. Minneapolis-based HistoSonics designed its Edison system to target and destroy targeted primary renal tumors. It achieves this in a non-invasive manner without the need for incisions or needles. Edison uses a novel sonic bean therapy called […]
J&J leads $85M raise for HistoSonics
HistoSonics announced today that it raised $85 million in a financing round led by Johnson & Johnson Innovation. Minneapolis-based HistoSonics develops a novel sonic beam therapy. This uses histotripsy, which mechanically destroys and liquified unwanted tissue and tumors at sub-cellular levels. It develops the non-invasive Edison platform that combines imaging with proprietary sensing technology to […]
HistoSonics, GE Healthcare agree to integrate ultrasound into sonic beam liver therapy
HistoSonics announced today that it agreed with GE Healthcare to use its ultrasound imaging to power novel sonic beam therapy. Minneapolis-based HistoSonics’ agreement formalizes ongoing efforts to use GE Healthcare’s Logiq E10 Series ultrasound imaging platform to power the real-time visualization features of HistoSonics’ sonic beam liver therapy platform. Under the agreement — and upon […]
HistoSonics announces $40m Series C
Non-invasive robotics platform and sonic beam therapy developer HistoSonics announced today that it closed a Series C-1 financing worth $40 million. Yonjin Venture led the oversubscribed funding round, while Varian Medical Systems, Johnson & Johnson Innovation, Venture Investors, Lumira Ventures, State of Wisconsin Investment Board and more participated as well, according to a news release. […]
HistoSonics touts first-in-human study results
HistoSonics said today that its non-invasive robotics platform and novel sonic beam cancer therapy successfully destroyed 11 tumors in eight patients during its first clinical trial. The results were presented this week at the 2019 Society of Interventional Oncology (SIO) Annual Meeting in Boston. The meeting also included preclinical presentations of what HistoSonics termed promising […]
Varian leads $54m Series C for HistoSonics
HistoSonics said today that it closed a $54 million Series C round led by Varian Medical (NYSE:VAR) that included a contribution from Johnson & Johnson (NYSE:JNJ). The Ann Arbor, Mich.-based company, which is developing an image-guided, robotically assisted platform using non-invasive and non-thermal technologies, said Lumira Ventures, Venture Investors, the State of Wisconsin Investment Board and […]
HistoSonics raises $5m
HistoSonics has raised $4.8 million in a new debt and warrants round of financing, according to a recently posted SEC filing. HistoSonics is developing an image-guided, robotically assisted platform therapy using non-invasive and non-thermal technologies, according to the company’s website. Money in the round came from 20 anonymous investors, with the first sale noted on […]
Relievant Medsystems taps ex-Cameron Health chief Hykes for CEO | Personnel Moves, Sept. 26, 2017
Relievant Medsystems said it named former Cameron Medical chief Kevin Hykes to be its new CEO, effective immediately. Hykes, who led Cameron Health to a $1.35 billion buyout in 2012 by Boston Scientific (NYSE:BSX), replaced Alex DiNello, who was named COO, Relievant said. Relievant makes the Intracept device for treating lower back pain. Hykes was most recently […]
HistoSonics pulls in $14M | Medtech funding for the week of May 19, 2014
HistoSonics nears close of $14.2M funding for non-invasive ablation
Michigan medical device maker HistoSonics is creeping toward the close of a $14.22 million funding round in support of its non-invasive tissue ablation technology.
The company has raised about $14.17 million so far from 13 unnamed investors, through sales of equity, options, warrants and other rights to acquire securities, according to an SEC filing dated May 16.
